The TMRSS2–ERG gene fusion is considered an early event in the development of prostate cancer, and it often coexists with PTEN deletion to drive frank carcinoma in around 20% of primary and 50% of advanced prostate tumors [44,94]. This evidence concerns the gene PTEN and prostate cancer.